Cis‐platinum Treatment of Metastatic Adrenal Carcinoma

Tattersall, Martin H. N.; Lander, H.; Bain, Barbara J.; Stocks, A.E.; Woods, Robert L.; Fox, Richard M.; Byrne, Elizabeth; Trotten, J. R.; Roos, Ian

doi:10.5694/j.1326-5377.1980.tb134997.x

Cited by 41 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common side effects were gastrointestinal, renal, and neurologic problems; the toxicity of the treatment was monitored and found to be moderate to severe. In other clinical studies the addition of mitotane to cisplatin did not enhance the response rate [53,55], in accordance with the concept that MDR-1 is not involved in cisplatin resistance.…”

Section: Single-agent Chemotherapysupporting

confidence: 82%

Cytotoxic treatment of adrenocortical carcinoma

et al. 2001

View full text Add to dashboard Cite

Adrenocortical carcinoma (ACC) is a rare, aggressive tumor that is often detected in an advanced stage. Medical treatment with the adrenotoxic drug mitotane has been used for decades, but critical prospective trials on its role in residual disease or as an adjuvant agent after surgical resection are still lacking. The concept of a critical threshold plasma level of the drug must be confirmed in controlled studies. Because individual responsiveness cannot be predicted, the use mitotane is still advised for nonresectable disease. In case of cortisol or other steroid overproduction, several drugs (e.g., ketoconazole or aminoglutethimide) may be used. Chemotherapy with single agents (e.g., doxorubicin or cisplatin) have been disappointing, with low response rates (< 30%) and a short response duration. Part of this refractoriness may be explained by the fact that ACC tumors express the multidrug-resistance gene MDR-1. Chemotherapy with multiple agents has been tested in smaller series and has resulted in significant side effects. The best results were achieved by the combination of etoposide, doxorubicin, and cisplatin associated with mitotane, achieving a response rate of 54%, including individual complete responses. To be able to make progress in treating advanced ACC disease, adjuvant multicenter trials must be encouraged. When mitotane-based therapies are used, monitored drug levels are mandatory.

show abstract

Section: Single-agent Chemotherapysupporting

confidence: 82%

Cytotoxic treatment of adrenocortical carcinoma

et al. 2001

View full text Add to dashboard Cite

show abstract

“…As the tumor is extremely rare controlled studies on chemotherapy for adrenocortical carcinoma do not exist. There is anecdotic evidence of tumor regression under cisplatin, etoposide, doxorubicin or 5-fluorouracil [Chun et al., 1983, Johnson and Greco, 1986, Schlumberger et al, 1988, van Slooten et al, 1983, Tattersall et al, 1980. The most extensively studied drug is mitotane which was introduced in the treatment of adrenocortical carcinoma in 1960 by Bergenstal and coworkers.…”

Section: Discussionmentioning

confidence: 99%

Complete remission of metatasized adrenocortical carcinoma under o,p'-DDD

Kornely

Schlaghecke²

2009

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

The case of a 53 year old female patient with metastasized androgen producing adrenocortical carcinoma is presented. After initial adrenalectomy a local relapse had been treated by surgery and external irradiation. Solitary liver metastases had been resected repeatedly. Subsequently multiple liver metastases required systemic chemotherapy. Treatment with o,p'-DDD (initially 12 g/d, long term treatment 1.5-3 g/d) has resulted in a complete remission for nearly 4 years. Gastrointestinal side effects occurred initially but subsided with dose reduction of o,p'-DDD.

show abstract

“…It proved ineffective. S -FU in combination with o, p'-DDD [ l , 1-dichloro-2-(-0chlorophenyl)-2-(p-chlorophenyl)-ethane] had resulted in complete cure in one patient [lS], but other reports of response to 5-FU in adults showed variable success [4, Although its use had not been reported in children, cisplatinum has proved beneficial in metastatic disease [19][20][21][22]. On that basis, a drug combination (OPEC-see case record) containing cisplatinum was chosen.…”

Section: Discussionmentioning

confidence: 99%

Combination chemotherapy for adrenal carcinoma: Response in a 5 1/2‐year‐old male

Crock

Clark

1989

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Adrenocortical carcinoma is an uncommon tumor of childhood, and systematic studies of therapeutic options are not available. Children with very large tumours have a poor outlook with surgery alone, so that other treatment should be considered, but the literature is unhelpful in suggesting what this should be. In the case reported here, combination chemotherapy, including cisplatinum, gave a well-documented good partial response, suggesting a possible role for adjuvant chemotherapy using such a drug combination.

show abstract

Cis‐platinum Treatment of Metastatic Adrenal Carcinoma

Cited by 41 publications

References 9 publications

Cytotoxic treatment of adrenocortical carcinoma

Cytotoxic treatment of adrenocortical carcinoma

Complete remission of metatasized adrenocortical carcinoma under o,p'-DDD

Combination chemotherapy for adrenal carcinoma: Response in a 5 1/2‐year‐old male

Contact Info

Product

Resources

About